Professor of Immunotherapy, University of Pennsylvania
Appears in 1 story
Pioneer of CAR-T cell therapy
Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns, lawsuits, and nearly ended the field. Fast forward to December 2025: British scientists published results showing that base-edited immune cells—a 'living drug'—achieved deep remissions in 82% of children with previously incurable T-cell leukemia. Three years after treatment, 64% remain disease-free. Some patients are off treatment entirely.
Updated Jan 9
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
